| Home | E-Submission | Sitemap | Editorial Office
top_img
    
REVIEW
Genetic predisposition in nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease whose prevalence has reached global epidemic proportions. Although the disease is relatively benign in the early stages, when severe clinical forms, including nonalcoholic steatohepatitis (NASH), c...
ORIGINAL ARTICLE
Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis
Background/Aims: Transient elastography (TE) has been proposed as a promising noninvasive alternative to hepatic venous pressure gradient (HVPG) for detecting portal hypertension (PH). However, previous studies have yielded conflicting results. We gathered evidence from literatu...
ORIGINAL ARTICLE
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
Background/Aims: The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment a...
ORIGINAL ARTICLE
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients
Background/Aims: A recent study reported that entecavir had inferior efficacy in nucleos(t)ide analogue (NA)-experienced chronic hepatitis B (CHB) patients compared to NA-naïve patients. We sought to compare the efficacy of tenofovir disoproxil fumarate (TDF) in NA-experienced a...
Current Issue
Volume 23(1); Mar 2017
Volume 22(4); December 2016
Volume 22(3); September 2016
Volume 22(2); June 2016
Volume 22(1); March 2016
RSS feed
  • Most-cited are based on citations from 2015 ~ 2017.

    KASL clinical practice guidelines: management of chronic hepatitis B
    Clin Mol Hepatol.2016;22(1):18-75.   Published online March 28, 2016     
    DOI: https://doi.org/10.3350/cmh.2016.22.1.18
                                     Cited By 16
    Hepatitis C virus-induced hepatocellular carcinoma
    Nicolas Goossens, Yujin Hoshida
    Clin Mol Hepatol.2015;21(2):105-114.   Published online June 26, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.2.105
                                     Cited By 15
    A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016
    Su Jong Yu
    Clin Mol Hepatol.2016;22(1):7-17.   Published online March 28, 2016     
    DOI: https://doi.org/10.3350/cmh.2016.22.1.7
                                     Cited By 13
    Clinical implications of advances in liver regeneration
    Yong Jin Kwon, Kyeong Geun Lee, Dongho Choi
    Clin Mol Hepatol.2015;21(1):7-13.   Published online March 25, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.1.7
                                     Cited By 12
    The mutational landscape of hepatocellular carcinoma
    Ju-Seog Lee
    Clin Mol Hepatol.2015;21(3):220-229.   Published online September 30, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.3.220
                                     Cited By 10
    Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis
    Yoon Ok Jang, Baek Gyu Jun, Soon Koo Baik, Moon Young Kim, Sang Ok Kwon
    Clin Mol Hepatol.2015;21(2):141-149.   Published online June 26, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.2.141
                                     Cited By 9
    Personalized management of cirrhosis by non-invasive tests of liver fibrosis
    Grace Lai-Hung Wong, Wendell Zaragoza Espinosa, Vicnent Wai-Sun Wong
    Clin Mol Hepatol.2015;21(3):200-211.   Published online September 30, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.3.200
                                     Cited By 8
    The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B
    In Ku Yo, Oh Sang Kwon, Jin Woong Park, Jong Joon Lee, Jung Hyun Lee, In Sik Won, Sun Young Na, Pil Kyu Jang, Pyung Hwa Park, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim
    Clin Mol Hepatol.2015;21(1):32-40.   Published online March 25, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.1.32
                                     Cited By 8
    Personalized treatment of hepatitis B
    Anna S. Lok
    Clin Mol Hepatol.2015;21(1):1-6.   Published online March 25, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.1.1
                                     Cited By 7
    New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis
    Hyun Young Woo, Jeong Heo
    Clin Mol Hepatol.2015;21(2):115-121.   Published online June 26, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.2.115
                                     Cited By 7
    Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase
    Yasuko Iwakiri
    Clin Mol Hepatol.2015;21(4):319-325.   Published online December 24, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.4.319
                                     Cited By 6
    The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease
    Goh Eun Chung, Donghee Kim, Min-Sun Kwak, Jong In Yang, Jeong Yoon Yim, Seon Hee Lim, Mustafa Itani
    Clin Mol Hepatol.2016;22(1):146-151.   Published online March 28, 2016     
    DOI: https://doi.org/10.3350/cmh.2016.22.1.146
                                     Cited By 6
    Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
    Han Na Choi, Jeong Eun Song, Hyeon Chul Lee, Hyeong Ho Jo, Chang Hyeong Lee, Byung Seok Kim
    Clin Mol Hepatol.2015;21(1):24-31.   Published online March 25, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.1.24
                                     Cited By 5
    Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease
    Chansik An, Youn Ah Choi, Dongil Choi, Yong Han Paik, Sang Hoon Ahn, Myeong-Jin Kim, Seung Woon Paik, Kwang-Hyub Han, Mi-Suk Park
    Clin Mol Hepatol.2015;21(3):279-286.   Published online September 30, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.3.279
                                     Cited By 5
    Imaging findings of mimickers of hepatocellular carcinoma
    Tae Kyoung Kim, Eunchae Lee, Hyun-Jung Jang
    Clin Mol Hepatol.2015;21(4):326-343.   Published online December 24, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.4.326
                                     Cited By 5
    Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
    Sang Kyung Jung, Kyung-Ah Kim, So Young Ha, Hyun Kyo Lee, Young Doo Kim, Bu Hyun Lee, Woo Hyun Paik, Jong Wook Kim, Won Ki Bae, Nam-Hoon Kim, June Sung Lee, Yoon Jung Jwa
    Clin Mol Hepatol.2015;21(1):41-48.   Published online March 25, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.1.41
                                     Cited By 5
    Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells
    Ha Ra Gu, Su Cheol Park, Su Jin Choi, Jae Cheol Lee, You Cheoul Kim, Chul Ju Han, Jin Kim, Ki Young Yang, Yeon Joo Kim, Geum Youb Noh, So Hyeon No, Jae-Hoon Jeong
    Clin Mol Hepatol.2015;21(1):49-59.   Published online March 25, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.1.49
                                     Cited By 5
    KASL clinical practice guidelines: management of hepatitis C
    The Korean Association for the Study of the Liver (KASL)
    Clin Mol Hepatol.2016;22(1):76-139.   Published online March 28, 2016     
    DOI: https://doi.org/10.3350/cmh.2016.22.1.76
                                     Cited By 5
    Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
    Jung Gil Park
    Clin Mol Hepatol.2015;21(3):287-294.   Published online September 30, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.3.287
                                     Cited By 4
    The cost of liver disease in Korea: methodology, data, and evidence
    Wankyo Chung
    Clin Mol Hepatol.2015;21(1):14-21.   Published online March 25, 2015     
    DOI: https://doi.org/10.3350/cmh.2015.21.1.14
                                     Cited By 3
  • Editorial Office
    The Korean Association for the Study of the Liver
    Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
    TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
    About |  Browse Articles |  Current Issue |  For Authors and Reviewers
    Copyright © The Korean Association for the Study of the Liver. All rights reserved.